NanoViricides Inc is a biotechnology business based in the US. NanoViricides shares (NNVC) are listed on the NYSE MKT and all prices are listed in US Dollars. NanoViricides employs 17 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $2.25 |
|---|---|
| 52-week range | $1.99 - $8.71 |
| 50-day moving average | $3.97 |
| 200-day moving average | $4.16 |
| Wall St. target price | $8.75 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.82 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.25 from 2022-01-24
| 1 week (2022-01-19) | -16.04% |
|---|---|
| 1 month (2021-12-23) | -42.89% |
| 3 months (2021-10-26) | -54.08% |
| 6 months (2021-07-26) | -46.30% |
| 1 year (2021-01-26) | -46.04% |
|---|---|
| 2 years (2020-01-24) | -73.37% |
| 3 years (2019-01-25) | 690.58% |
| 5 years (2017-01-26) | 99.12% |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -18.61% |
| Return on equity TTM | -31.31% |
| Profit margin | 0% |
| Book value | $2.46 |
| Market capitalisation | $25.9 million |
TTM: trailing 12 months
We're not expecting NanoViricides to pay a dividend over the next 12 months.
NanoViricides's shares were split on a 1:20 basis on 23 September 2019. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NanoViricides shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for NanoViricides shares which in turn could have impacted NanoViricides's share price.
Over the last 12 months, NanoViricides's shares have ranged in value from as little as $1.99 up to $8.71. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while NanoViricides's is 0.5905. This would suggest that NanoViricides's shares are less volatile than average (for this exchange).
NanoViricides, Inc. , a nano-biopharmaceutical research and development company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction; HerpeCide Dermal Topical and Eye Drops for the treatment of shingles, PHN, chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis; and HerpeCide IntraOcular Injection for viral acute retinal necrosis The company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide, which is injectable for hospitalized patients and oral for outpatients; Nanoviricide eye drops for viral diseases of the external eye; DengueCide for treatment of various types of Dengue viruses; and HIVCide, an escape-resistant anti-HIV nanoviricide. In addition, it develops other nanoviricides drug projects for treatment of different viruses and indications; and HerpeCide program expansion drug projects for different herpes viruses for different indications. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut. .
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.